BAY 866150

Drug Profile

BAY 866150

Alternative Names: BAY 86-6150; BAY VII; Factor VIIa - Bayer; Maxy 968; MAXY-VII

Latest Information Update: 20 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Maxygen
  • Developer Bayer HealthCare
  • Class Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemophilia A; Haemophilia B

Most Recent Events

  • 20 Aug 2013 Discontinued - Phase-I for Haemophilia A in United Kingdom (Parenteral)
  • 20 Aug 2013 Discontinued - Phase-I for Haemophilia B in United Kingdom (Parenteral)
  • 20 Aug 2013 Discontinued - Phase-II/III for Haemophilia A in Bulgaria, Poland, Singapore, South Korea, South Africa and Ukraine (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top